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Abstract
Background: A substantial proportion of cancer cases present with a metastatic tumor and require further testing
to determine the primary site; many of these are never fully diagnosed and remain cancer of unknown primary origin
(CUP). It has been previously demonstrated that the somatic point mutations detected in a tumor can be
used to identify its site of origin with limited accuracy. We hypothesized that higher accuracy could be achieved by a
classification algorithm based on the following feature sets: 1) the number of nonsynonymous point mutations
in a set of 232 specific cancer-associated genes, 2) frequencies of the 96 classes of single-nucleotide substitution
determined by the flanking bases, and 3) copy number profiles, if available.
Methods: We used publicly available somatic mutation data from the COSMIC database to train random forest
classifiers to distinguish among those tissues of origin for which sufficient data was available. We selected feature
sets using cross-validation and then derived two final classifiers (with or without copy number profiles) using
80 % of the available tumors. We evaluated the accuracy using the remaining 20 %. For further validation, we
assessed accuracy of the without-copy-number classifier on three independent data sets: 1669 newly available
public tumors of various types, a cohort of 91 breast metastases, and a set of 24 specimens from 9 lung cancer
patients subjected to multiregion sequencing.
Results: The cross-validation accuracy was highest when all three types of information were used. On the
left-out COSMIC data not used for training, we achieved a classification accuracy of 85 % across 6 primary
sites (with copy numbers), and 69 % across 10 primary sites (without copy numbers). Importantly, a derived
confidence score could distinguish tumors that could be identified with 95 % accuracy (32 %/75 % of tumors
with/without copy numbers) from those that were less certain. Accuracy in the independent data sets was
46 %, 53 % and 89 % respectively, similar to the accuracy expected from the training data.
Conclusions: Identification of primary site from point mutation and/or copy number data may be accurate
enough to aid clinical diagnosis of cancers of unknown primary origin.
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Background
Cancer arises as a result of changes in the genomes of
healthy cells; thus every tumor holds a set of mutations
that reflect the transformational process as well as the
selective pressure that shaped the tumor. Specific types
of cancer are often driven by mutations, amplification,
or deletions of specific oncogenes or tumor suppressor
genes that are rarely or never observed in other types of
cancer. For example, the proto-oncogene KRAS is found
mutated in ~42 % of colorectal tumors but in less than
1 % of breast tumors; whereas amplification of ERBB2 is
found in ~13 % of breast tumors but in only ~3 % of
colorectal tumors [1]. With the increasing amount of
cancer sequencing data available, we hypothesized that it
may be possible to identify broad patterns in mutation
or copy number profiles that can be used to distinguish
among various cancer types.
A method to infer the tissue origin or site of a tumor
could be useful in the diagnosis and treatment of meta-
static cancer. Around 10–15 % of cancer patients
present with metastatic cancer; in many of these cases
the primary tumor cannot be readily located [2]. After
histopathology and specialized investigations such as
colonoscopy, CT scans, etc., 2–4 % of all cancers remain
“cancers of unknown primary” (CUPs) [3]. If a genomic
test could identify the most likely primary site of a meta-
static tumor, this could enable more efficient treatment
as well as improve patient outcomes. Indeed, early re-
sults suggest that exome sequencing can be used to sug-
gest likely primary sites for CUPs [4].
A second prospective application of a genomic test to
locate the origin of cancer is in the context of blood or
urine screening programs for early detection of cancer.
The detection and sequencing of cell-free circulating
tumor DNA (ctDNA), as well as circulating tumor cells
(CTCs), has recently been demonstrated for several can-
cer types [5]. As this technology develops, blood or urine
sequencing may become standard to screen individuals
at high risk of developing cancer. If cancer-implicated
mutations are found in these fluids, a method to immedi-
ately deduce the location of the tumor directly from these
mutations could enable quicker diagnosis and treatment
of the disease.
Several genomic features have been systematically
compared across, and found to differ between, various
cancer types [6]. The pattern of gain or loss of spe-
cific chromosome regions, or copy number profile,
has been explored by cytogenetic and hybridization-
based methods [7–9]. Tumor-specific enrichment for
mutations in certain genes, sometimes at specific po-
sitions within the gene, has been observed, and also
used to infer tumor localization [10, 11]. The fre-
quency of specific base substitutions, both alone and
in the context of the two flanking bases, also seems
to follow tissue-specific patterns [12, 13] and may reflect
specific chemical or enzymatic mutational processes.
We aimed to determine how well the somatic muta-
tions, here defined as a collective term for somatic
point mutations and somatic copy number aberrations
(SCNAs), found in a tumor can be used to infer its pri-
mary tissue of origin. The quality and quantity of data
from tumor genome (or exome) sequencing can vary;
therefore we developed and compared performance of
classification algorithms utilizing various types and
amounts of information. Specifically, we hypothesized
that copy number profiles would add to the classifier
performance. However, although tumor copy number
profiles can be derived from whole genome or whole
exome sequence data [14], the quality and reliability de-
pends on adequate sequencing depth, and is therefore
not available for all sequenced samples. Thus, we evalu-
ated classifiers based on somatic point mutations only,
here used as a collective term for single nucleotide sub-
stitutions, short insertions and deletions, and classifiers
based on point mutations as well as SCNAs, separately.
Methods
Somatic mutation training data
We downloaded all somatic point mutation data (Cos-
micMutantExport_v68.tsv.gz) from the COSMIC data-
base version 68 [15, 16] corresponding to 235,589
specimens. We removed 227,512 specimens not labeled as
“Genome.wide.screen” and 5,064 specimens labeled as
cell-line (in union 227,757 specimens). In ten cases, two
sample IDs matched to the same tumor ID, meaning one
tumor gave rise to two samples in the data set. In 105
cases, the same sample name matched to more than one
tumor ID. Specimens were removed to leave only one
sample per tumor ID. When deciding which specimen to
keep, the following priorities were made: Surgery biopsy,
primary, verified and exome seq had priority over xeno-
graft, relapse, unverified and RNA-Seq, respectively. The
resulting data set consisted of 7,769 specimens from 28
different primary sites.
Gene annotation was not entirely consistent and thus
required additional curation. We mapped as many genes
as possible to Ensembl gene IDs, by searching for gene in-
formation in the following columns: Accession.Number,
HGNC.ID, and Gene.name, which in most cases con-
tained the gene symbol, but was also found to hold
Ensembl gene IDs and Swissprot accession numbers.
We were able to annotate Ensembl gene IDs to 99.4 %
of the point mutations in COSMIC. Finally, point mu-
tations in COSMIC are reported for all possible tran-
scripts, so we filtered the mutation table so that each
row corresponded to a single unique mutation identi-
fied by its genomic position.
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We also downloaded all available SCNA data (Cosmic-
CompleteCNV_v68.tsv.gz) from the COSMIC v68 data-
base [16] and mapped the genes overlapping with each
SCNA segment.
Derivation of features
Non-synonymous mutations The point mutation status
of a gene was defined for each sample by querying the
point mutation data for each pair of sample ID and
Ensembl gene ID. If any point mutation was found, dis-
regarding those annotated as “coding silent” in the
Mutation.Description column, that gene was called as
mutated in that sample.
Base substitution frequency There are six classes of
single base substitutions, which we name according to
the pyrimidine of the germline Watson-Crick base pair
(C > A, C > G, C > T, T > A, T > C and T > G). For each
sample, all substitution mutations were used to calculate
the relative frequency of each of the six classes.
Trinucleotide base substitution frequency For single
nucleotide substitutions defined by their trinucleotide
context, only single base substitutions were counted,
and the flanking bases were extracted from the reference
genome hg19 using fastahack [17]. The resulting trinu-
cleotides were standardized (center base as the pyrimi-
dine), and the relative frequency of each of the 96
different classes was calculated.
Copy number aberrations For each sample, the copy
number status of each gene was defined according to the
copy number of any SCNA segments that overlapped,
entirely or partially, with the gene. Copy number status
was encoded as −1, 0 or +1, corresponding to a loss, no
change or gain of copy number.
Machine learning
We considered four commonly used machine learning
methods: stepwise additive logistic regression, artificial
neural networks, support vector machines, and random
forests. We anticipated that presence or absence of mu-
tations in 232 genes recurrently mutated in cancer [10]
along with the six single base substitution frequencies
would allow fairly good discrimination between primary
sites, and used these features to evaluate the perform-
ance of these four machine learning methods on the
training data. For each method, we trained an ensemble
of ten classifiers, each intended to discriminate one
primary site from the other nine. Based on cross-
validation accuracy, we found that random forests pro-
vided the best performance across the 10 primary sites
(Additional file 1: Figure S3).
Random forest classifiers [18] were trained using the
randomForest [19] package v.4.6-7 in R, using the de-
fault parameters to grow 500 trees, and sample
ﬃﬃﬃ
p
p
fea-
tures as candidates at each split within a tree, where p is
the total number of features. Stratified sampling was
used to draw equal numbers of cases and non-cases for
each tree, with sample size equal to 0.632 times the size
of the smallest group. When applied to a new data sam-
ple, we define the “classification score” as the proportion
of the trees that voted for the given primary site. All data
matrices used for training, testing and validation are
available in Additional file 2: Table S2.
Validation data
SAFIR01 and MOSCATO trials Mutation calls based
on whole exome sequencing data for a cohort of 91 meta-
static breast cancers was obtained from the Department of
Medical Oncology, Gustave Roussy, Villejuif, France from
the trials SAFIR01 (NCT01414933) [20] and MOSCATO
(NCT01566019). Genomic DNA was captured using
Agilent in-solution enrichment methodology with their
biotinylated oligonucleotides probes library (SureSelect
Human All Exon v5 – 50 Mb, Agilent), according to
the manufacturer’s instructions, followed by paired-end
75 bases massively parallel sequencing on Illumina
HiSeq 2500. For detailed explanations of the process,
see [21]. Image analysis and base calling was performed
using Illumina Real Time Analysis (RTA) Pipeline ver-
sion 1.12.4.2 with default parameters. FASTQ files were
aligned to the reference genome hg19 with the BWA
mem algorithm [22]. After alignment, the BAM files
were filtered for PCR duplicate reads, then sorted and
indexed with samtools [23] for further analyses. We used
the Mutect and GATK Haplotype Caller algorithms [24]
for identifying substitutions and the IndelGenotyper and
GATK Haplotype Caller algorithms [25] for identifying
small insertions and deletions (indels). Somatic mutations
were defined with the following filters: frequency of the
reads with the altered base in the tumor ≥ 10 %; number
of reads with the altered base in the tumor ≥ 5; frequency
of the reads with the altered base in the normal < 2 %;
number of reads with the altered base in the normal < 4.
The resulting somatic mutations were annotated with the
snpEff and snpSift algorithms [26].
COSMIC v70 We downloaded all somatic point muta-
tion data from the COSMIC database version 70 [27]
and removed any mutations with a sample ID also found
in version 68, which was used for training, or with a pri-
mary site different from the ten primary sites that were
used to train our model, resulting in data from 1669
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tumors. We curated the gene annotations as described
for the training data.
NSCLC cohort In the non-small cell lung cancer patient
cohort study (UCLHRTB 10/H1306/42), tumor specimens
were collected from patients who were eligible for surgical
resection at the University College London Hospitals NHS
Foundation Trust. For each tumor region and matched
germ-line, exome capture was performed on 1-2 μg
DNA using either the Agilent Human All Exome V4 kit
or Illumina Nextera Exome Enrichment kit according
to the relevant manufacturer’s protocol. Samples were
paired-end multiplex sequenced on the HiSeq 2500 at
the Advanced Sequencing Facility at the London Re-
search Institute, as described previously [28, 29]. Raw
paired end reads in FastQ format generated by the Illu-
mina pipeline were aligned to the full hg19 genomic as-
sembly (including unknown contigs) obtained from
GATK bundle 2.8, using bwa mem (bwa-0.7.7) [22],
Picard tools v1.107 was used to clean, sort and merge
files from the same patient region. Picard was also used
to remove duplicate reads [30]. A combination of pic-
ard tools (1.107), GATK (2.8.1) and FastQC (0.10.1)
were used to generate quality control metrics. SAM-
tools mpileup (0.1.16) [23] was used to locate non-
reference positions in tumour and germ-line samples.
Bases with a phred score of <20 or reads with a
mapping-quality <20 were skipped. BAQ computation
was disabled and the coefficient for downgrading map-
ping quality was set to 50. Somatic variants between
tumour and matched germ-line were determined using
VarScan2 somatic (v2.3.6) [31] utilizing the output from
SAMtools mpileup. Default parameters were used with
the exception of minimum coverage for the germ-line
sample that was set to 10, minimum variant frequency
was changed to 0.01 and tumour purity was set to 0.5.
VarScan2 processSomatic was used to extract the som-
atic variants. The resulting SNV calls were filtered for
false positives using Varscan2’s associated fpfilter.pl
script. Additionally the SNVs were filtered based on
variant allele frequency ≥ 5 % and a count of the num-
ber of reads containing the variant ≥ 5.
Ethics, consent and permissions All patients included
in the SAFIR01 and MOSCATO trials gave their in-
formed consent for translational research and genetic
analyses of their germline DNA. The NSCLC tumor
samples were collected as part of the UCL/UCLH Bio-
bank for Studying Health and Disease based at the UCL
Cancer Institute, with prior ethical approval (UCLHRTB
10/H1306/42). All study procedures were performed in
accordance with national clinical research guidelines.
Availability
A website implementing the two final classifiers (PM and
PM+CN, as described below) is freely available [32]. Both
classifiers require the user to supply 1) a VCF file, and 2)
an SNV file, as output by either MuTect or VarScan. The
PM+CN classifier additionally requires a table containing
the copy number segments and their associated copy
number calls. In the current implementation, genomic po-
sitions must be specified in hg19/GRCh37 coordinates
only. Primary sites covered by both classifiers are breast,
endometrium, kidney, large intestine, lung and ovary, and
in addition the PM classifier also covers liver, pancreas,
prostate and skin.
Results
Development of a classifier based on somatic point
mutations
We used the COSMIC version 68 Whole Genomes
database to identify tumor specimens with genome-
wide or exome-wide somatic point mutation data, and
focused on solid non-CNS tumors of the ten primary
sites for which at least 200 unique specimens were
available (Table 1). CNS tumors were not included be-
cause extraneural metastases of these tumors are rare
[33], and 200 specimens were required to allow for a
reasonable number of tumors of each primary site
within each cross-validation training and test set. The
resulting 4,975 specimens were split randomly, while
retaining proportionality of each class, into a training
set of 3,982 specimens used to derive the classifier, and
a test set of 993 specimens that was not used except to
evaluate the final classifier. We used five-fold cross val-
idation on the training set to select the feature sets as
described below. For each primary site a binary random
Table 1 Number of specimens available in the COSMIC whole
genomes v68 database, with point mutations (PM) or with both
point mutations and copy number aberrations (PM+ CN), including
those in the training set and those in the testing set. Categories
with counts <200 were not analyzed and are omitted here
Primary site PM PM + CN
Breast 936 850
Endometrium 281 246
Kidney 468 300
Large intestine 592 486
Liver 415
Lung 807 476
Ovary 497 462
Pancreas 311
Prostate 372
Skin 296
Total 4975 2820
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forest classifier was trained to distinguish that site from
all other sites. When these classifers were applied to
test samples, classifications were made for the primary
site with the highest classification score (Fig. 1).
Selection of features
We aimed to identify a set of features derived from the
point mutation data that could most accurately identify
the primary site of a tumor. We used five-fold cross val-
idation to assess the classification accuracy using various
combinations of the following sets of features:
Mutation status of recurrent cancer genes For each
sample, we determined the number of non-synonymous
point mutations occurring within the coding regions of
each of 232 genes that are recurrently mutated in can-
cer [10]. When training a model with these features
alone we achieved a cross-validation accuracy of 55 %
across the ten primary sites (Fig. 2a). Accuracy varied
among primary sites, from 36 % for liver to 78 % for
large intestine.
Single base substitution frequency Single base substi-
tutions are found at different frequencies across tumors,
likely reflecting the mutational processes that shaped the
tumor genome. For example, carcinogens in tobacco
smoke cause C to A transitions, which are found fre-
quently in lung tumors. For each tumor sample, we used
all base substitution mutations, regardless of their effect,
to calculate the relative frequencies of the six different
classes of single base substitutions. This feature set alone
classified primary site with an overall accuracy of 48 %,
but when combined with the point mutation feature set
described above accuracy increased to 65 % (Fig. 2a).
Trinucleotide-context base substitution frequency
The imprint left by some mutational processes may not
be fully discernible at the single-base resolution, and
subclassification of the mutations by their trinucleotide
sequence context has previously been used to decipher
mutational signatures in cancer [34]. For each tumor
sample, we used all single nucleotide substitution muta-
tions and their flanking 5’ and 3’ bases to calculate the
relative frequencies of the 96 possible trinucleotide mu-
tations. This feature set alone identified primary site
with an overall accuracy of 58 %, but when combined
with the point mutation feature set described above ac-
curacy increased to 66 % (Fig. 2a).
Development of a classifier based on somatic point
mutations and copy number aberrations
We next considered whether copy number profiles could
improve classification performance. However, SCNA
data is available from the COSMIC Whole Genomes
database for only ~60 % of the specimens in our training
data. Thus, we assessed the performance of classifiers
96 base 
substitution 
frequencies
232 genes
mutation 
status
232 genes 
copy number 
status
Somatic
point
mutations 
Copy
number
Large 
intestine
Kidney
Endo-
metrium
Breast
Lung
OvaryLiver
Pan-
creas
Prostate
Skin
Input data
Feature
extraction
random forest 
Output
scores
Ranked
sites for top-ranked site
Fig. 1 Classifier outline. Somatic point mutation data is used to determine the mutation status of a set of cancer genes and to calculate the
distributions of 96 classes of base substitutions. When copy number profiles are available, they are used to infer any SCNAs in the same set of
cancer genes. These features are combined and provided to a set of random forest classifiers, one per primary site, each of which generates a
classification score. The PM classifier does not use copy number profiles and is trained to distinguish between all 10 primary sites. The PM + CN
classifier does use copy number profiles (orange), but can only distinguish between 6 primary sites (white) due to less training data. Thus, blue
boxes are components of the the PM classifier only, and orange boxes are components of the PM + CN classifier only, and white boxes are
components of both classifiers. These sites were selected based on the availability of sufficient training data (>200 cases)
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using a set of SCNA features in a separate analysis, re-
ducing the number of samples and thereby also the
number of primary sites from ten to six (Table 1). This
increases the expected accuracy of a random classifier
from 1/10 = 10 % to 1/6 = 17 %, and so for proper com-
parison we repeated some of the previous analyses on
the reduced data set. In this reduced data set, the point
mutation feature set alone classified primary site with an
accuracy of 69 % (Fig. 2b).
Each of the 232 genes that we previously encoded as a
feature in the nonsynonymous mutation set was also
encoded as a copy number feature (loss, gain or normal
copy number). Using the copy number feature set alone
resulted in an accuracy of 80 %, and when combined
with the point mutation feature set increased to 85 %.
Further adding one or both sets of base substitution fre-
quencies and trinucleotide frequencies increased accur-
acy to 87–88 % (Fig. 2b).
We used the cross-validation-based results to assess
which feature sets to use in a final classifier of primary
site. In addition to the 232 genes, with features for their
nonsynonymous mutation and where possible copy num-
ber status, we found that, overall, the use of trinucleotide-
context base substitution frequencies provided the highest
accuracy (66.6 % and 87.6 %, for classifiers with and with-
out copy number aberrations, respectively, Fig. 2). There-
fore, we trained final classifiers using these feature sets on
the entire training data set, hereinafter termed the PM
and PM+CN classifiers.
Performance of PM and PM + CN classifiers on test data
We applied these two classifiers to the fraction of COS-
MIC data that had been set aside as test data, and
achieved an overall accuracy of 69 % and 85 % with the
PM and PM+CN classifiers, respectively (Figs. 3a and 4a).
We noticed that certain pairs of tissues (e.g., breast–
ovary, breast–prostate, and endometrium–ovary) seem
to be frequently confused (Fig. 3a), and that the classi-
fiers for these pairs of tissues in some cases produce
elevated classification scores for the same specimen
(Additional file 1: Figure S1). Therefore, we defined a
“confidence score” as the difference between the individ-
ual classification scores for the two highest-scoring
tissues. We found that the confidence score was indeed
a strong indicator of accuracy, and that a large fraction
of tumors could be classified with high confidence
(Figs. 3c–d, 4c–d and Additional file 1: Figure S2).
In a clinical application, it would be valuable to pro-
duce a ranked list of likely tissues, suggesting the order
in which these tissues might be examined in a patient.
Thus, we ranked the scores of the individual tissue-
specific classifiers and assessed the accuracy of the cu-
mulative tissue list; i.e., how frequently the correct tissue
is in the top n proposed tissues (Figs. 3b and 4b). At any
number of tissues, our method was substantially more
accurate than either random lists or a list of tissues
ranked by frequency in the data set.
Clinical features influencing classifier performance
To investigate whether the performance of the PM and
PM+ CN classifiers is biased by certain clinical features
of tumors, we analysed the subset of tumors in our
COSMIC-derived training data that originated from
TCGA, and for which we could retrieve clinical annota-
tions based on sample names directly from the TCGA
repository. We split the tumors according to the validity
of the predicted primary site during cross validation or
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final testing, and examined stage, grade and subtype for
any subgroup with a significantly unequal distribution
among the correct and incorrect subsets (Table 2). We
found that wrongly-classified samples were enriched
with statistical significance for triple-negative vs. estro-
gen receptor-positive and Her2-positive breast cancer,
and higher vs. lower grade in endometrial cancer. In
addition, micro-satellite instabile (MSI) tumors were
more frequent among wrongly-classified tumors of the
large intestine, whereas in endometrial tumors MSI was
more frequent among correctly classified tumors.
Performance of PM classifier on independent validation
cohorts
Our classifiers were developed using the data in COS-
MIC version 68. As an independent validation set we
downloaded COSMIC version 70 point mutation data,
and filtered out any specimens that were already entered
in v68. This data is reasonably independent from the
training data, because all data analysis steps such as
quality control, alignment, mutation calls, etc., which
could have added a systematic bias, were performed by
the authors of the original publications rather than by
COSMIC. From this independent validation set of 1669
samples from 9 primary sites we could derive the point
mutation and trinucleotide frequency feature sets, based
on which our model achieved accuracy slightly lower
than expected from the test set, yet still substantially
higher than random classification (Fig. 5a).
Next, we applied the PM classifier to point mutation
calls from 91 metastatic breast tumors from SAFIR01, a
clinical trial to assess benefit of exome sequencing for
metastatic breast cancer. These calls were derived from
whole exome sequencing of metastasis biopsy specimens
and matched blood samples. Our method correctly pro-
posed breast as the primary site in 53 % of the samples
(Fig. 5b). This is slightly lower than the breast-specific
specificity of 61 % on the test set (Fig. 3a). After breast,
the most commonly proposed sites were ovary (21 %)
and prostate (11 %).
Finally, we applied the PM classifier to point mutation
calls from whole exome sequencing of 24 specimens
from 9 non-small cell lung cancer (NSCLC) patients in a
cohort study in which multiple regions from the same
lesion were sequenced to study intratumor heterogeneity.
In addition, lymph node metastases had been analysed in
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some cases. When pooling the mutations called in all
specimens of a lung tumor, our method correctly pro-
posed lung as the primary site in eight out of nine tumors
(Fig. 5c). When the 24 specimens were analysed individu-
ally, we found that the majority of the subregions and me-
tastases were proposed to be of the same origin as the
pooled specimens (Fig. 6).
Comparison of the PM classifier with an existing method
To our knowledge there are no previously published
studies that use copy number aberrations to infer the
primary site of a tumor. However, there is one study
aimed at inferring tumor primary site from point muta-
tions [11]. In brief, Dietlein and Eschner used mutation
data from 905 cell lines originating from 23 different
tumor primary sites to select the set of position-specific
and -nonspecific mutations with the highest discrimin-
atory power for a single primary site. They used this data
to train their tool, ICOMS, to infer cancer origin from a
mutation profile. Thus, we sought to compare our
method to ICOMS. Unfortunately, an implementation of
ICOMS was not provided with the publication. However,
ICOMS was validated on a set of 431 tumors from
TCGA, of which 297 were present in the version of
COSMIC that we used to develop our PM classifier.
In light of this, we found this set of overlapping
tumors would provide the least biased comparison be-
tween the two methods that was currently feasible.
We compared ICOMS calls to our calls obtained for
cross-validation test sets, and compared both to the
actual primary sites, and found that ICOMS made
125 correct calls, whereas our classifier made 232
correct calls (Additional file 3: Table S1).
However, the two algorithms deal with uncertainty in
different ways: ICOMS in some cases proposes no pri-
mary site, whereas our classifiers always propose a site
along with a corresponding confidence score. Therefore,
we did a second analysis omitting the n samples with
lowest confidence scores generated by our classifier, in
which n was the number of samples for which ICOMS
made no proposal, and compared the performance of
each method on the 109 samples for which both
methods proposed a primary site. Accuracy, defined as
the percentage of samples for which the correct primary
site was inferred, was significantly higher by our classi-
fier than by ICOMS (96 % vs. 83 %, p = 0.003).
Discussion
We developed proof-of-concept classifiers designed to
identify the primary site of a tumor from its genomic
profile. Specifically, our most accurate classifier used the
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Table 2 Some clinical subgroups are associated with increased or decreased performance of the primary site classifiers PM and PM
+ CN
PM PM + CN
Primary site Subgroup Acc. (%) N P Acc. (%) N P
Subtype
Breast ER 64 417 0.064 91 416 0.00033 **
HER2 63 146 0.31 91 138 0.037 *
TNBC 27 98 4.1 × 109 ** 40 97 3.3 × 1018 **
Endometrium MSI 77 71 0.015 * 93 70 3 × 105 **
MSS 54 157 0.17 59 156 0.038 *
Large intestine MSI 97 68 0.091 74 68 8.6 × 105 **
MSS 88 233 0.48 97 230 0.0075 **
Ovary mBRCA1 76 55 0.097 96 55 0.56
mBRCA2 79 39 0.077 97 38 0.5
wtBRCA 61 338 0.29 92 333 0.58
Stage
Breast Stage I 65 129 0.24 82 127 0.6
Stage II 59 437 0.95 84 432 0.93
Stage III 57 175 0.55 84 172 1
Stage IV 47 15 0.43 87 15 1
Kidney Stage I 80 153 0.8 95 149 1
Stage II 81 32 1 91 32 0.44
Stage III 81 78 0.87 97 77 0.39
Stage IV 88 43 0.39 88 42 0.18
Large intestine Stage I 89 65 0.82 94 64 1
Stage II 90 143 0.87 91 141 0.45
Stage III 89 101 0.85 93 101 1
Stage IV 94 49 0.6 98 49 0.35
Lung Stage I 79 261 0.7 82 257 0.53
Stage II 78 106 0.69 84 105 0.88
Stage III 87 97 0.16 89 95 0.27
Stage IV 74 19 0.56 89 18 1
Grade
Endometrium G1 74 76 0.055 88 76 0.0022 **
G2 73 75 0.073 86 73 0.0088 **
G3 41 92 0.0013 ** 45 92 1.2 × 105 **
Kidney G1 71 7 0.61 100 7 1
G2 84 128 0.68 93 125 0.66
G3 80 122 0.68 96 120 0.63
G4 82 45 1 93 44 0.73
Ovary G1 0 3 0.056 33 3 0.014 *
G2 60 55 0.77 87 54 0.098
G3 63 405 0.83 95 394 0.47
G4 0 1 0.38 100 1 1
Information on subtype, grade and stage were retrieved from TCGA, and are therefore not available for all tumors in the COSMIC database. ER estrogen receptor
positive. HER2 human epidermal growth factor receptor 2 positive. TNBC triple negative breast cancer. MSI microsatellite instability. MSS microsatellite stable.
mBRCA1 mutated BRCA1. mBRCA2 mutated BRCA2. wtBRCA wildtype BRCA1 and BRCA2. Acc. accuracy ie. the percentage of tumors correctly classified. N the
number of tumors in subgroup. P p-value from Fisher’s exact test comparing accuracy among samples in or not in each subgroup. *p < 0.05. **p < 0.01
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point mutation and copy number status of a set of 232
genes recurrently mutated in cancer, as well as the relative
frequencies of 96 classes of base substitutions. As more
mutation data becomes available, it will likely be possible
to increase accuracy and to develop classifiers for add-
itional primary sites, which may involve additional genes.
In many cases, tumor material as well as resources for
sequencing may be limited, and we therefore evaluated
how well our algorithms performed in the context of less
extensive or fewer types of data. We found that the type
of feature that best identifies primary site on its own is
the copy number profile. Copy number profiles can be
inferred along with point mutations from sequencing
data of sufficient depth [14], and the use of assays such
as SNP arrays that measure copy number but not point
mutations may thus become less frequent as sequencing
A
cc
ur
ac
y 
(%
)
0
20
40
60
80
100
Number of proposed tumor types
1 3 5 7 92 4 6 8 10
a
A
cc
ur
ac
y 
(%
)
0
20
40
60
80
100
Number of proposed tumor types
1 3 5 7 92 4 6 8 10
b
A
cc
ur
ac
y 
(%
)
0
20
40
60
80
100
Number of proposed tumor types
1 3 5 7 92 4 6 8 10
c
Fig. 5 Performance of the PM classifier on independent validation data. a Tumors of various types from COSMIC v70 (n = 1669). b Metastatic
breast tumors from the SAFIR01 trial (n = 91). c Multiregion-sequenced non-small cell lung cancer (n = 9). See Fig. 3b legend. For comparison,
the expected performance of our method in each data set was estimated according to the distribution of primary sites and the site-specific
accuracies on test data
R1 R2 R3
0.0
0.2
0.4
0.6
0.8
1.0
C
on
fid
en
ce
 s
co
re L012
R1 R2 R3
L013
R2 R3
L016
R1 R2 R3
0.0
0.2
0.4
0.6
0.8
1.0
C
on
fid
en
ce
 s
co
re L017
R1 L1 L2 L3
L019
R1 R2 L1
L022
R1 R2
0.0
0.2
0.4
0.6
0.8
1.0
C
on
fid
en
ce
 s
co
re L023
R1 R2
L029
R1 R2
L030
Kidney Large intestine Lung
Fig. 6 Consistency of the PM classifier on data from multiple samples from the same tumor. The classifier was applied to 24 specimens from
9 NSCLC patients, including primary regions (R) and lymph node metastases (L). The proposed primary site is indicated by color along with
the confidence score
Marquard et al. BMC Medical Genomics  (2015) 8:58 Page 10 of 13
costs decrease. Also, even though SCNA data provides
notable increase in performance, using point mutation
data alone still results in classification with an accuracy
sufficiently high to be of clinical interest. A classifier
using point mutations but not SCNAs could be pre-
ferred if sequencing depth or sample purity were not
sufficient to infer copy numbers from sequencing data,
or if point mutations were called from targeted sequen-
cing of a restricted gene set.
Our classifiers were trained on data found in COS-
MIC, much of which comes from larger studies of many
tumors of the same primary site. This introduces the
possibility of bias resulting from confounding factors
such as experimental or analytical protocols, which may
explain why we observed slightly reduced performance
in two of three independent validation data sets relative
to what would be expected based on training data per-
formance. The effect of this possible bias will be reduced
as more data from multiple studies becomes available.
Our method does not use raw DNA sequence as input
but instead relies on lists of point mutations, which are
the output of algorithms designed to call mutations from
sequence data. Several mutation calling algorithms exist,
and there are extensive discrepancies between their out-
put [35]. These discrepancies may influence the per-
formance of our method, as well as any other method
relying on point mutation calls.
Other studies have addressed the important problem
of determining the primary site of tumors by molecular
profiling, but most previous reports have used gene ex-
pression profiles from microarrays [36] or quantitative
PCR [37], or in a few cases microRNA expression profil-
ing [38, 39]. It is a recognized problem that gene expres-
sion based classifiers do not perform well on poorly
differentiated tumor samples, presumably because dif-
ferentiation is driven by gene expression changes. In
addition, a major source of circulating microRNAs are
blood cells, and the levels of many reported tumor cir-
culating microRNA biomarkers correlate with blood
cell counts [40, 41]. Accordingly, genomic profiling
provides a more robust and cancer-specific measure-
ment, which is unlikely to be directly affected by cell
differentiation, and for this reason we believe a method
for tumor classification based on DNA rather than
RNA is needed. One such method, based on point mu-
tations alone, has previously been described [11], yet
our method, using the same data, performed better on
the subset of samples for which we were able to com-
pare the two methods. Since both methods include
consideration of mutations in specific genes, we believe
that part of the increased performance of our method
stems from using the base substitution frequencies,
which reflect the mutational processes that shaped the
genome of the tumor [13]. The frequencies of different
base substitutions included in our model capture some
information about the exogenous DNA-damaging pro-
cesses that were at play in the precancerous cells, which
are often tissue specific, such as tobacco carcinogens in
lung tissue, but may also reveal endogenous processes,
such as common transition mutations at CpG dinucleo-
tides in gastrointestinal cancers, hypothesized to reflect
higher levels of methylation in these tumor types [12].
Classifiers such as ours may be useful for establishing
the primary site in patients with metastatic disease of
unknown origin, in order to direct patients to the most
optimal treatment. For this application, it may be pos-
sible to increase classification accuracy by considering
additional clinical or pathological features such as ex-
pression of tissue-characteristic proteins, or the location
of the metastasis. The latter has been reported in a few
studies, in which the authors developed classifiers based
on observed associations between distinct metastatic
and primary sites [42, 43]. These methods achieved an
accuracy of 51–64 %, and the combination of such a
method with a molecular profiling method such as ours
is likely to improve the overall accuracy.
In the future, our method to infer the primary site of
tumor cells may be applicable to mutations discovered
by sequencing of circulating tumor DNA in blood or
urine, which may be applied for early detection or moni-
toring of cancer, as deep sequencing of low levels of
tumor DNA becomes increasingly possible [44]. For any
of these applications, it will be important to calibrate the
classifiers to reflect both individual patient risk and the
tissue-specific probability of a tumor being detected.
Conclusions
Our method can be used to identify the likely primary
site of a tumor specimen with sufficient accuracy to be
clinically useful. This can be used to help diagnose can-
cers of unknown primary origin, or to identify the origin
of circulating tumor cells or DNA found in blood-based
screens.
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